Animal models, screening methods, and treatment methods for intraocular diseases or disorders

A method of treating age-related macular degeneration (AMD) in a subject in need thereof, the method comprising administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula III, or a pharmaceutically acceptable salt thereof,

• wherein Ar20 is an optionally substituted aryl ring, or an optionally substituted heteroaryl ring;
• L20 is null, an optionally substituted C1-6 alkylene, an optionally substituted C1-6 heteroalkylene, an optionally substituted C2-6 alkenylene, an optionally substituted C2-6 alkynylene, an optionally substituted C3-6 cycloalkylene, an optionally substituted arylene, an optionally substituted heteroarylene, or an optionally substituted 4-7 membered heterocyclylene,
• W20 is —OR1;
• —COR2;
• —COOR1a;
• —OCOOR1a;
• —NR3R4, —CONR3aR4a, —OCONR3bR4b;
• —SO2NR3cR4c;
• —OSO2NR3dR4d, —SR5;
• —SO2R5a;
• —OCOR2a;
• —OSO2R5a;
• or
• wherein:
• R1 and R1a are each independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted heterocyclyl;
• R3 and R4 are each independently hydrogen, —COR2b, —SO2R5b, optionally substituted C1-6 alkyl, optionally substituted C2-6 alkenyl, optionally substituted C2-6 alkynyl, optionally substituted C3-6 cycloalkyl, optionally substituted phenyl, optionally substituted 5 or 6 membered heteroaryl, or optionally substituted 4-7 membered heterocyclyl, or R3 and R4 together with the atoms they are bound to form an optionally substituted 4-7 membered heterocyclyl;
• R2, R2a, R2b, R5, R5a, and R5b are each independently hydrogen, —OH, —NR3eR4e, an optionally substituted C1-6 alkyl, an optionally substituted C2-6 alkenyl, an optionally substituted C2-6 alkynyl, an optionally substituted C1-6 alkoxy, an optionally substituted C3-6 cycloalkyl, an optionally substituted C3-6 cycloalkoxy, an optionally substituted phenyl;
• an optionally substituted 5 or 6 membered heteroaryl;
• or an optionally substituted 4-7 membered heterocyclyl;
• and
• R3a, R3b, R3c, R3d, R3e, R4a, R4b, R4c, R4d, and R4e are each independently hydrogen, an optionally substituted C1-6 alkyl, an optionally substituted C2-6 alkenyl, an optionally substituted C2-6 alkynyl, an optionally substituted C1-6 alkoxy, an optionally substituted C3-6 cycloalkyl, an optionally substituted C3-6 cycloalkoxy, an optionally substituted phenyl;
• an optionally substituted 5 or 6 membered heteroaryl;
• or an optionally substituted 4-7 membered heterocyclyl;
• or R3a and R4a, R3b and R4b, R3c and R4c, R3d and R4d, or R3e and R4e, together with the atoms they are bound to form an optionally substituted 4-7 membered heterocyclyl.